to allocate samples, to design continuing medical education programs and direct-to-consumer campaigns, and to evaluate the effects of specific promotions on sales. Internally, pharmaceutical companies use prescription tracking to identify physicians to target, to delineate sales force territories, and to evaluate and compensate sales representatives who receive bonuses based on drug sales in their area. 2, 3 Prescription information is collected by health information organizations (HIOs), which have monitored prescriptions via surveillance technologies since the 1950s. 4 Access to information regarding the prescriptions of individual physicians has been available since 1989. 5 HIOs, also known as data-mining companies, act as brokers of this information, which they package from different sources to create detailed prescribing portraits of each physician. IMS Health is the largest HIO; others include Dendrite, Verispan, and Wolters Kluwer. 6 Pharmacies, the primary source of prescribing data, sell patients' prescription records that include the date, medication name, dose, and directions. Specific unique numbers are substituted for patient names. Prescribers are identified by number (usually state license or Drug Enforcement Administration numbers). IMS obtains records on about 70% of prescriptions filled in community pharmacies. 6 Prescription information is also obtained from pharmacy benefit managers and wholesalers. 3 In the United States, HIOs are able to reassociate physician identifiers with physician names by purchasing information from the American Medical Association (AMA), which maintains the Physician's Masterfile, a database that contains demographic information on all U.S. physicians. 6 Currently, the Masterfile includes approximately 900,000 M.D.s and D.O.s in the United States. 7 According to a company that licenses Masterfile data, the AMA also receives "student information from medical schools, residency information from residency program directors, and practice information from over 2,100 different resources including medical organizations, institutions and government agencies." 8 The AMA has sold doctors' demographic data to the pharmaceutical industry continuously since the 1940s. 4 In contrast, Canada, Europe, and many other countries do not allow industry access to information on each physician's prescriptions. Prescribing data for groups of physicians (known as "bricks") are available, but not for individual physicians. 2 In the U.S., not only are individual physicians' prescriptions minutely monitored, but so are their patients' medical records. Although patient names are not included, information gathered on individuals may include age, sex, geographic location, medical conditions, hospitalizations, laboratory tests, insurance copays, and medication use. 9 Although detailed information is tracked on individuals over time, this commercial use of medical records complies with the Health Insurance Portability and Accountability Act (HIPAA), a federal statute that provides some medical privacy protections, because patient names are not included. Instead, unique numbers identify each individual. 9 PharMetrics, a unit of IMS, has a database that "contains >2 [billion] health care events including the complete set of pharmacy and medical claims of >55 million Americans."
10 "Anonymized patient-level data" refines industry knowledge of physicians' prescribing behavior by revealing "first-and secondline usage, diagnosis, compliance/persistency, and referral patterns." 11 Patient-level data "can help marketers understand which strategy will have the greatest effects on sales." 11 In other words, the linkage of medical claims with prescription data allows HIOs to offer pharmaceutical companies detailed information on every physician's referral networks, patients, and preferred treatments for specific diagnoses in specific patient subpopulations. These data, usually updated on a weekly basis, allow ongoing analyses of how a physician's prescribing behavior responds to personally tailored marketing strategies.
THE PDRP
In recent years, prescription tracking has become a controversial issue among physicians. Several state legislatures have introduced bills restricting prescription tracking. The AMA met with industry and surveyed physicians, finding that although two-thirds of physicians opposed the availability of prescribing data to drug representatives, 77% of those would have their concerns alleviated if doctors could choose to protect their individual prescribing information. 3 In response to industry and physician concerns, the AMA created the Prescription Data Restriction Plan (PDRP). Interested physicians visit a website (http://www.ama-assn.org/go/ prescribingdata) and fill out a form requesting that their prescribing data be withheld from pharmaceutical sales representatives. To activate one's PDRP rights online, a physician must check off or provide a reason for opting out and accept the vaguely ominous statement that, "Some of the information provided may be shared with entities outside the AMA in order to register and/or follow up on your concern." Requests expire 3 years from when the physician signs up, and requests may take 6 months to take effect because drug companies are required to check the list quarterly and then have 90 days to restrict sales representatives access to these data. 12 A pilot version of the PDRP was launched in California and several other states in May 2006; the program officially launched nationally in July 2006. 7 Few doctors know about the PDRP. Soon after the program launched, a poll of 210 physicians found that only 18% were aware of the program; more than half (53%) were interested in signing up. 13 The AMA mailed no announcements to physicians because studies have shown that "direct mail to physicians is very inefficient," according to the AMA's Media Outreach Coordinator, 7 who also noted that office staff often intercept physicians' mail. Instead, the AMA placed ads or announcements in AMA publications and several medical journals, and e-mailed announcements to about 100,000 physicians, about 1,000 of whom subsequently signed up for the PDRP. 7 By July 18, 2006, 2,900 of 800,000 practicing physicians had signed up for the PDRP. 13 By May 2007, a year after the program began, about 1% of active physicians (7,476) doctors had opted out.
14 By January 2008, almost 12,000 doctors (65% of whom are not AMA members) have signed up. 15 Such low participation in the PDRP is predictable because opt-out options "are designed to maximize participation while preserving a patina of choice." 16 Default choices are perceived to be socially preferable, so opt-out options have resulted in increased default participation in situations as diverse as prenatal HIV testing, 401(k) savings plans, and medical journal reviewing. 16 In its current form, the PDRP withholds some information from some industry representatives some of the time. Individual prescribing information is withheld only from pharmaceutical representatives and their immediate supervisors. All other employees retain full access to all the individual-specific prescribing information. As an industry article puts it, "The information available to the 'home office' will not change, regardless of physician enrollment in PDRP. This program will not affect headquarter business systems." 17 The most relevant information is still available to pharmaceutical representatives because the PDRP exempts information on "(a) deciles at the market or therapeutic class level, (b) segmented data that are not likely to reveal the actual or estimated activity of an individual physician, or (c) data on products ordered by physicians from pharmaceutical companies." 17 In other words, the PDRP does not restrict pharmaceutical companies from seeing, analyzing, and using prescribing data to promote specific drugs to the doctors who have opted out. However, the pharmaceutical representatives and managers are still provided the information that Dr. X is in the top 10% of doctors in terms of prescribing volume for antidepressants; in the top 20% for antibiotics; and is an "early adopter" of drugs. Pharmaceutical representatives enjoy full access to drugspecific details on chemotherapy or any other drugs dispensed or administered in physicians' offices. An industry article notes that that although the PDRP "limits reps and their supervisors from accessing data on some physicians, it nonetheless enable companies to continue to run essential business applications that rely on prescriber data." 17 Whereas a massive physician sign-up of high prescribers for the PDRP would inconvenience pharmaceutical companies, "the opt-outs to date are generally lower-prescribing physicians, with 72% in the market-five decile or lower." 3 Doctors in the bottom half of prescribers are not targeted for marketing anyway.
AN ALTERNATIVE TO LAW
In 2006, New Hampshire passed a law banning commercial sale of prescribing data and was promptly sued by IMS and Verispan. On April 30, 2007, a federal judge ruled the New Hampshire law unconstitutional on the grounds that it restricts commercial free speech. 18 The state plans to appeal the decision.
Other states are considering similar bills, but the decision in New Hampshire and the availability of the PDRP has had an effect. A preliminary injunction was granted to prevent enforcement of a Maine law (which is also being appealed), and Vermont is now modifying a law that it passed. 15 The availability of the PDRP was key to a 2006 decision not to reintroduce California Assembly Bill 262 (narrowly defeated in 2004), which would have severely restricted the sale and use of prescription data. 5 An industry publication explains, "Pharmaceutical manufacturers need to make the PDRP work, since the alternative, government legislation, is not in anyone's best interest. Without PDRP, long-term access to physician-level data within the healthcare system is called into question." 5 The AMA's PDRP brochure states that the program "responsibly honors the opinions of all physicians-and provides a more reasonable alternative to a "one-size-fits-all" legislative ban that ignores vital aspects of prescribing data use." 19 The industry-friendly nature of the PDRP is revealed in an article coauthored by AMA and IMS employees, which states, "The rules allow the industry to retain access to prescribing data for most purposes, but they require companies to police their own sales forces. If they succeed, legislators will turn their attention elsewhere, and the industry can hang onto one of its most valuable data sources." 17 
RISKS AND BENEFITS OF RX TRACKING
Pharmaceutical interests argue that unrestricted access to prescribing data saves lives, money, and physicians' time. The Pharmaceutical Research and Manufacturers of America (PhRMA) has argued that prescriber data are needed to send out communications informing doctors of drug recalls and serious adverse effects. 20 However, when the FDA orders a recall or mandates a new black box warning on a drug, the manufacturer is usually required to send a "Dear Health Care Provider" letter to all U.S. prescribers, not just to those who recently prescribed the drug. PhRMA also argues that, "Access to prescriber data allows pharmaceutical companies to target necessary prescription information to physicians which helps avoid a saturation of less relevant information to a broader physician audience." 20 An industry article states that, "Prescribing data allow pharmaceutical promotion to be relevant and specific, making the whole process more cost-effective (and sparing physicians from being bombarded with extraneous promotional materials and sales calls)…." 17 Certainly, these data enable the identification of physicians relevant and specific to drug sales. Sales calls and promotional materials are preferentially showered on highprescribing physicians and others who affect market share. 1 The AMA, in testimony opposing legislation to restrict industry access to prescriber data, states that, "this information is critical to improving the quality, safety, and efficacy of providing patient care through evidence-based medical research." 21 The AMA is misguided on this point. Researchers do not need HIO data, which are too expensive for most individual researchers to purchase anyway. 4 (IMS has occasionally provided limited data to some researchers without cost or at discount. 20 Anecdotally, free data are older data and do not contain dates of service or other information routinely provided to paying customers.) Although HIOs claim that the FDA relies on their data, the use of HIO data by the FDA for public health purposes is trivial. According to IMS' 2006 Annual Report, "Sales to the pharmaceutical industry accounted for substantially all of our revenue in 2006, 2005, and 2004." 22 It bears noting that HIOs are not the only source of prescription data. Medicare, Medicaid, the military, the Veteran's Administration, and large health maintenance organizations (HMOs) all have databases of medical and prescription information that have been extensively used by health services researchers. Databases of large HMOs can be used to examine commercially insured populations. The inclusion of race and ethnicity data makes Medicaid ideal for researching health outcomes in diverse populations (Medicaid covers 1 in 5 Americans, including 1 in 3 African Americans and 1 in 4 Latinos). 23 Government data may be the most reliable for research purposes. One recent analysis found prescription data available from the Center for Medicaid and Medicare Services (CMS) superior to Medicaid data available from a commercial vendor. 24 The coverage of outpatient prescription drugs through
Medicare Part D will create a trove of prescription data on elders for researchers. Public health research rarely requires the identification of individual physicians. HIOs package physicians' names with prescriptions and patient medical records to facilitate pharmaceutical marketing efforts to manipulate individual prescribing habits.
There is no obligation for HIOs to share information with government regulators-even when such information affects public health. For example, sluggish sales of a migraine drug in 2003 led an unnamed company to hire IMS Health to determine why. 25 IMS researchers hypothesized that lowerthan-forecasted sales of the migraine drug could be because of decreased menopausal hormone use. Millions of women stopped taking menopausal hormones in mid-2002 when the Women's Health Initiative showed that risks outweighed benefits for the most popular estrogen-progestin regimen. IMS examined the medical records of 41,403 women with migraines and found that those who stopped hormone therapy halved their use of migraine drug prescriptions. Women filled an average of 2.94 prescriptions for migraine medication during a 6-month period on hormone therapy compared with an average of 1.49 prescriptions during a 6-month period after they stopped hormones. More than half of the women (54%) filled no migraine drug prescriptions in the 6 months after quitting hormones. 25 This very large study, which definitively linked migraines and hormone therapy, was never shared with physicians nor published in the medical literature. It was mentioned, in a publication directed exclusively at pharmaceutical marketers, as an example of the services HIOs provide to pharmaceutical companies. What other marketing studies with implications for public health are hidden in industry files? Pharmaceutical companies are required by law to report adverse events associated with their products to the FDA. HIOs should also be required to report adverse effects of therapies they study.
The commercial sale and use of prescriptions and medical records compromises the privacy of individual prescribers and patients, is not necessary for health services research, and may well have adverse effects on public health. The purpose of prescription tracking is to promote the use of the newest, most expensive drugs, a practice that threatens rational prescribing.
Assessment of the benefits and harms of medications should be a government function, implemented by researchers without commercial ties, and conducted solely in the public health interest. Public monies should be allocated to integrate existing public sources of health data and expand accessibility to researchers who will use these data in the interests of patients rather than industry profits.
